Department of Thoracic Surgery, European Institute of Oncology IRCCS, Milan, Italy.
Department of Thoracic Surgery, European Institute of Oncology IRCCS, Milan, Italy.
Ann Thorac Surg. 2021 Jul;112(1):271-277. doi: 10.1016/j.athoracsur.2020.07.069. Epub 2020 Oct 14.
In stage III to IVa thymic epithelial tumors (TETs), infiltration of the superior vena cava (SVC) is not rare. The extent of SVC resection depends on the width of the area of neoplastic invasion. Our article aims to evaluate the safety and long-term outcomes of extended thymectomy for TETs with SVC resection compared with advanced-stage TETs patients without SVC resection.
Retrospective review of the experience on patients who underwent extended thymectomy for TETs in the last 20 years, according to STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) methodology. Progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method. A backward stepwise Cox regression multivariate analysis was performed to determine factors associated with long-term outcomes.
A total of 78 patients underwent surgery for advanced-stage TETs (Masaoka-Koga stages III-IVa) from January 1998 to April 2019. Fourteen (17.9%) underwent thymectomy with resection of SVC. Presence of a thymic carcinoma (hazard ratio , 2.26; 95% confidence interval, 1.82-6.18; P = .038) and the SVC resection (hazard ratio, 1.89; 95% confidence interval, 1.11-3.96; P = .041) were adverse prognostic factors at multivariate analysis. The median OS and the PFS of all SVC resected patients were 50 (range, 5-207) months and 31 (range, 5-151) months, respectively. There was no significant difference in OS (P = .28) and PFS (P = .32) between SVC-resected and non-SVC-resected patients.
SVC resection is a safe and effective procedure to restore the venous system continuity and does not seem to affect survival and disease recurrence. This surgical approach allows radical resection of locally advanced TETs, even after neoadjuvant chemotherapy.
在 III 期至 IVa 期胸腺癌(TET)中,上腔静脉(SVC)浸润并不罕见。SVC 切除的范围取决于肿瘤侵袭区域的宽度。我们的文章旨在评估与未行 SVC 切除术的晚期 TET 患者相比,行 SVC 切除术的 TET 患者接受广泛胸腺切除术的安全性和长期结果。
根据 STROBE(加强观察性研究的报告)方法,回顾性分析过去 20 年来接受广泛胸腺切除术治疗 TET 的患者经验。采用 Kaplan-Meier 法计算无进展生存率(PFS)和总生存率(OS)。采用向后逐步 Cox 回归多因素分析确定与长期结果相关的因素。
1998 年 1 月至 2019 年 4 月,共有 78 例患者因晚期 TET(Masaoka-Koga 分期 III-IVa)接受手术治疗。其中 14 例(17.9%)行胸腺切除术联合 SVC 切除术。多因素分析显示,存在胸腺癌(危险比,2.26;95%置信区间,1.82-6.18;P=0.038)和 SVC 切除术(危险比,1.89;95%置信区间,1.11-3.96;P=0.041)是不良预后因素。所有 SVC 切除患者的中位 OS 和 PFS 分别为 50(范围,5-207)个月和 31(范围,5-151)个月。SVC 切除组与未切除组的 OS(P=0.28)和 PFS(P=0.32)无显著差异。
SVC 切除术是恢复静脉系统连续性的安全有效方法,似乎不会影响生存和疾病复发。这种手术方法允许对局部晚期 TET 进行根治性切除,甚至在新辅助化疗后也是如此。